AB
AEON BiopharmaClinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a biosimilar to Botox, for therapeutic indications like cervical dystonia and chronic migraine.
1 Pulse story
FT
Flare TherapeuticsFlare Therapeutics is a clinical-stage biotech developing small-molecule drugs that target transcription factors, including a first-in-class ARON-targeting degrader for prostate cancer.
2 Pulse stories
Total Raised
$290M
AEON BiopharmaFlare Therapeutics
Last ValuationNot disclosed
Biotech
Sector
Biotech
2013
Founded
2021
Irvine, California
HQ
Cambridge, Massachusetts
Public (AEON)
Status
Private
AEON Biopharma investors
No investors on record.
Flare Therapeutics investors
Third Rock VenturesNextech InvestPfizer VenturesBoxer CapitalGordonMD Global InvestmentsInvusCasdin CapitalEli Lilly and Company
Data from Value Add Pulse coverage and company research — see the full threads for AEON Biopharma and Flare Therapeutics.